omada health will prescribe glp-1 drugs starting in 2026. jumps into GLP-1s as Trump inks deal to lower drug costs Major insurance changes are coming

Visit Dr

The Takeaway GLP1 drugs like semaglutide and liraglutide have reshaped diabetes and obesity treatment, and theyre now generating excitement in Alzheimers research

Tirzepatide reduces LV mass and paracardiac adipose tissue in obesity-related heart failure: SUMMIT CMR substudy

The use of short acting GLP-1RA drugs has shown to improve glycemic control and promote insulin sectretion (53)

10.2337/db14-1577 72 ZhaiR.XuH.HuF.WuJ.KongX.SunX

Across the full GLP-1 and obesity drug space, the post-2026 picture is a price-expansion wave led by Indian and Chinese biosimilars and by new dual or triple-agonist molecules, yet real uptake in the USA and EU will be shaped less by tariffs and more by regulatory timing, drug-device parity on pens and human-factors equivalence for AB-substitution, secondary IP and Orange Book hurdles, and payer or formulary contracting